Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Non-cash Items (2020 - 2025)

Tango Therapeutics has reported Non-cash Items over the past 6 years, most recently at $13.2 million for Q4 2025.

  • Quarterly results put Non-cash Items at $13.2 million for Q4 2025, up 509.85% from a year ago — trailing twelve months through Dec 2025 was $13.2 million (up 509.85% YoY), and the annual figure for FY2025 was $13.2 million, up 17.54%.
  • Non-cash Items for Q4 2025 was $13.2 million at Tango Therapeutics, down from $59.8 million in the prior quarter.
  • Over the last five years, Non-cash Items for TNGX hit a ceiling of $87.9 billion in Q3 2023 and a floor of $2.2 million in Q4 2024.
  • Median Non-cash Items over the past 5 years was $59.8 million (2025), compared with a mean of $16.2 billion.
  • Biggest five-year swings in Non-cash Items: surged 1688.69% in 2023 and later crashed 99.99% in 2024.
  • Tango Therapeutics' Non-cash Items stood at $51.4 billion in 2021, then crashed by 52.8% to $24.3 billion in 2022, then plummeted by 99.74% to $62.6 million in 2023, then crashed by 96.56% to $2.2 million in 2024, then soared by 509.85% to $13.2 million in 2025.
  • The last three reported values for Non-cash Items were $13.2 million (Q4 2025), $59.8 million (Q3 2025), and $20.8 million (Q2 2025) per Business Quant data.